Disciplined approach to drug discovery and early development
- 27 July 2016
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (349), 349ps15
- https://doi.org/10.1126/scitranslmed.aaf2608
Abstract
Our modern health care system demands therapeutic interventions that improve the lives of patients. Unfortunately, decreased productivity in therapeutics research and development (R&D) has driven drug costs up while delivering insufficient value to patients. Here, I discuss a model of translational medicine that connects four components of the early R&D pipeline—causal human biology, therapeutic modality, biomarkers of target modulation, and proof-of-concept clinical trials. Whereas the individual components of this model are not new, technological advances and a disciplined approach to integrating all four areas offer hope for improving R&D productivity.Keywords
This publication has 28 references indexed in Scilit:
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016
- When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisPLOS ONE, 2016
- 2015 FDA drug approvalsNature Reviews Drug Discovery, 2016
- The support of human genetic evidence for approved drug indicationsNature Genetics, 2015
- An analysis of the attrition of drug candidates from four major pharmaceutical companiesNature Reviews Drug Discovery, 2015
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional frameworkNature Reviews Drug Discovery, 2014
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004